Novavax (NVAX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.32
- Estimate
- -$0.38
- Surprise
- +16.6%
- Revenue (period 2026-06-30)
- $56.7M
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
Novavax (NVAX) reported a narrower loss than forecast — adjusted EPS of -$0.32 against the -$0.38 estimate (a 16.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates NVAX Sell at 4.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +16.6% surprise compares with a +69.7% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-4.2% upside)
- Quality below floor (2.3 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.82
- Price target
- $13.11
- Stop
- $11.92
- Upside to target
- +2.3%
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
NVAX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.11B
- P/E (fwd)
- -78.2
- 52-week range
- $6.20–$13.39
- Off 52-week high
- 4.3%
- RSI (14)
- 68
- Volume vs avg
- 0.99×
- Score today
- 4.9/10